Corbus Pharma

Corbus Pharma Corbus (Nasdaq: CRBP) is connecting innovation to purpose to improve the futures of cancer and obesity patients.

06/04/2026

Corbus CEO, Yuval Cohen, Ph.D., will present a corporate overview today, June 4th, at 4:55 EDT at the Jefferies Global Healthcare Conference. Watch the webcast here: https://bit.ly/4tysmC6

06/02/2026

Tune-in on Thursday, June 4th at 4:55pm EDT for Corbus CEO Yuval Cohen's presentation at the Jefferies Global Healthcare Conference. For webcast details: https://bit.ly/4tysmC6

05/31/2026

Tune-in on tomorrow, June 1st for a KOL event featuring updated data from the Phase 1/2 clinical study of CRB-701 in over 75 participants with head and neck squamous cell carcinoma.

The event will be held at the Marriott Marquis Chicago beginning at 6:30AM CT and will also be available virtually. Data to be discussed include clinical response durability and patient subgroup analysis presented as a poster at .

Featured experts:
• Ari Rosenberg, MD — University of Chicago Medicine
• Glenn Hanna, MD — Dana-Farber Cancer Institute
• Cesar Augusto Perez Batista, MD — Sarah Cannon Research Institute

Register here: https://bit.ly/3QS9MHC

05/30/2026

Reminder: An abstract featuring updated data from Corbus' Phase 1/2 study CRB-701 in patients with recurrent or metastatic head and neck squamous cell carcinoma will be presented today, May 30th at 4:30 PM CDT (Abstract 6062). For more info: https://bit.ly/4f9pb0k

05/29/2026

We look forward to sharing updated data from our Phase 1/2 clinical study of CRB-701 in at the 2026 American Society of Clinical Oncology Annual Meeting and to discussing these data at our KOL event on June 1st in Chicago.

At the event, Corbus CEO Yuval Cohen will host three leading experts — Ari Rosenberg, MD (University of Chicago Medicine), Glenn Hanna, MD (Dana-Farber Cancer Institute), and Cesar Augusto Perez Batista, MD (Sarah Cannon Research Institute) — for a discussion of updated data in over 75 HNSCC participants, including clinical response durability and patient subgroup analysis. A live Q&A session will follow.

Attendance is available in person at the Marriott Marquis Chicago (6:30AM CT) or virtually. Register here: https://bit.ly/3QS9MHC

05/28/2026

Attending the 2026 American Society of Clinical Oncology Annual Meeting? An abstract featuring updated data from Corbus' Phase 1/2 study CRB-701 in patients with recurrent or metastatic cervical cancer will be presented tomorrow, May 29th at 4:57 PM CDT (Abstract 5508). For more info: https://bit.ly/4f9pb0k

05/27/2026

Join us on Monday, June 1st for a KOL event to review and discuss updated data from the Phase 1/2 clinical study of CRB-701, which will be presented at , featuring insights from leading experts:

• Ari Rosenberg, MD – University of Chicago Medicine
• Glenn Hanna, MD - Dana-Farber Cancer Institute
• Cesar Augusto Perez Batista, MD - Sarah Cannon Research Institute

Register here: https://bit.ly/3QS9MHC

05/27/2026

ICYMI - Glenn Hanna, M.D., Director of the Center for Cancer Therapeutic Innovation at Dana-Farber Cancer Institute, joined Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, to discuss updated CRB-701 data being presented at which affirms Corbus's strategy of targeting tumor types with elevated Nectin-4 expression and clear unmet medical needs.

Listen here: https://bit.ly/4dx2kJC

05/26/2026

"These data provide important clarity on the clinical and commercial path for CRB-701 in 2L oropharyngeal and cervical cancers, indications that are both associated with HPV infection, and few available effective therapies," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. Read more: https://bit.ly/4f9h83K

05/26/2026

Corbus today reported updated data from its Phase 1/2 study of CRB-701, a next-generation Nectin-4 ADC, demonstrating robust activity in second-line oropharyngeal squamous cell carcinoma (OPSCC) and cervical cancer. Data will be presented at the upcoming 2026 ASCO Annual Meeting, May 29 – June 2 in Chicago.

Corbus will host a conference call and live webcast today, Tuesday , May 26 at 8:00 a.m. EDT, to review the data. Learn more: https://bit.ly/4f9h83K

Address

500 River Ridge Drive, Second Floor
Norwood, MA
02062

Telephone

+16179630100

Website

Alerts

Be the first to know and let us send you an email when Corbus Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Corbus Pharma:

Shortcuts

Share

Category